top of page
tokers-guide-find-the-best-weed-in-dc-lo
NEW 1 to 1 photo editing 122024 (17).png
A House subcommittee voted to block federal marijuana rescheduling, challenging the Trump administration's move to reclassify medical cannabis. The funding bill also maintains protections for state medical marijuana programs while allowing federal enforcement of penalties for distribution near schools.

House Lawmakers Try to Kill Cannabis Rescheduling Progress Despite White House Support

Apr 30, 2026

Source:

Tom Angell

Marijuana Moment

The political landscape for cannabis just got a bit more complicated, as a Republican-controlled House subcommittee recently voted to stop federal funds from being used to move forward with rescheduling. This decision directly challenges the Trump administration's recent efforts to reclassify the plant. It’s a classic case of D.C. friction, but for those of us who just want fair access to our favorite herb, there is still plenty of reason to stay optimistic.

Despite this pushback, the Department of Justice has already made some major moves. Specifically, any cannabis products currently regulated under state medical licenses have already been shifted to Schedule III. This is a massive win for patients across the country, providing immediate federal recognition and protection for those using the plant for health and wellness. While this new congressional "rider" tries to slam the brakes on future progress, it’s unclear if it can actually roll back the changes that have already taken effect for medical users.

There is even more good news buried in the fine print of this funding bill. For the first time, Nebraska has been added to the list of states protected from federal interference regarding their medical programs. This is a huge relief for residents in the Cornhusker State who voted for legalization back in 2024. Furthermore, the bill continues to protect state hemp research, showing that even with some political resistance, the overall momentum toward sensible reform is hard to stop.

For the everyday enthusiast, this means the industry is still moving in the right direction, even if the road has a few bumps. While politicians hash out the details on Capitol Hill, the transition to Schedule III for medical products is a significant step toward better research, lower taxes for businesses, and safer access for everyone. Keep an eye on the administrative hearings scheduled for this summer—that’s when we’ll likely see the next big push for broader rescheduling that covers the entire community. Stay informed and stay positive; the green wave is still rolling!

Recent Reviews

bottom of page